Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis

Abstract Background Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD. M...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Panupong Hansrivijit, Wisit Cheungpasitporn, Charat Thongprayoon, Nasrollah Ghahramani
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMC 2020-04-01
Serie:BMC Nephrology
Soggetti:
Rituximab
FSGS
Focal segmental glomerulosclerosis
MCD
Minimal change disease
Nephrotic syndrome
Accesso online:http://link.springer.com/article/10.1186/s12882-020-01797-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi